CareDx Inc
CDNA12.810USD
+0.590+4.83%
Horário de mercado （ET）Cotações atrasadas em 15 min
710.48MValor de mercado
12.07P/L TTM
Mais detalhes de CareDx Inc Empresa
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
Informações da empresa
Código da empresaCDNA
Nome da EmpresaCareDx Inc
Data de listagemJul 17, 2014
CEOMr. John W. Hanna
Número de funcionários644
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 17
Endereço8000 Marina Blvd
CidadeBRISBANE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94005
Telefone14152872300
Sitehttps://www.caredx.com/
Código da empresaCDNA
Data de listagemJul 17, 2014
CEOMr. John W. Hanna
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
298.28K
-3.24%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
144.69K
+9.13%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
143.65K
+0.86%
Jessica Meng
Jessica Meng
Chief Commercial Officer
Chief Commercial Officer
114.33K
+117.46%
Mr. Abhishek Jain
Mr. Abhishek Jain
Chief Financial Officer
Chief Financial Officer
110.14K
-8.07%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Ms. Christine M. Cournoyer
Ms. Christine M. Cournoyer
Independent Director
Independent Director
38.58K
+45.71%
Mr. Jeffrey Adam Novack
Mr. Jeffrey Adam Novack
General Counsel, Secretary
General Counsel, Secretary
30.76K
-0.89%
Caroline Corner
Caroline Corner
Investor Relations
Investor Relations
--
--
Ms. Jennifer Foley
Ms. Jennifer Foley
Chief Product Officer
Chief Product Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
298.28K
-3.24%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
144.69K
+9.13%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
143.65K
+0.86%
Jessica Meng
Jessica Meng
Chief Commercial Officer
Chief Commercial Officer
114.33K
+117.46%
Mr. Abhishek Jain
Mr. Abhishek Jain
Chief Financial Officer
Chief Financial Officer
110.14K
-8.07%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Detalhamento da receita
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Testing Service revenue
61.92M
0.00%
Digital and other revenue
11.95M
0.00%
Product revenue
10.81M
0.00%
Por RegiãoUSD
Nome
Receita
Proporção
United States
79.86M
0.00%
Rest of the world
4.82M
0.00%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Testing Service revenue
61.92M
0.00%
Digital and other revenue
11.95M
0.00%
Product revenue
10.81M
0.00%
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
8.66%
BlackRock Institutional Trust Company, N.A.
7.56%
State Street Global Advisors (US)
4.46%
Baron Capital Management, Inc.
3.93%
Gagnon Securities LLC
3.83%
Other
71.55%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
8.66%
BlackRock Institutional Trust Company, N.A.
7.56%
State Street Global Advisors (US)
4.46%
Baron Capital Management, Inc.
3.93%
Gagnon Securities LLC
3.83%
Other
71.55%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
44.53%
Investment Advisor
41.96%
Hedge Fund
10.10%
Individual Investor
3.41%
Research Firm
2.92%
Pension Fund
0.57%
Bank and Trust
0.32%
Family Office
0.04%
Venture Capital
0.04%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
455
56.93M
102.27%
-3.71M
2025Q1
463
58.20M
104.56%
-2.86M
2024Q4
457
54.99M
99.23%
-4.48M
2024Q3
452
53.78M
101.72%
-11.43M
2024Q2
424
54.82M
104.96%
-13.18M
2024Q1
450
55.58M
107.13%
-14.92M
2023Q4
462
54.27M
100.29%
-16.52M
2023Q3
493
55.98M
103.34%
-21.97M
2023Q2
517
57.57M
107.02%
-21.82M
2023Q1
532
58.67M
109.28%
-16.17M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
4.82M
8.66%
-25.66K
-0.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.21M
7.56%
-77.53K
-1.81%
Mar 31, 2025
State Street Global Advisors (US)
2.48M
4.46%
-174.50K
-6.56%
Mar 31, 2025
Baron Capital Management, Inc.
2.19M
3.93%
-17.29K
-0.78%
Mar 31, 2025
Gagnon Securities LLC
1.42M
2.55%
-9.51K
-0.66%
Mar 31, 2025
ARK Investment Management LLC
2.35M
4.22%
-61.72K
-2.56%
Mar 31, 2025
Invesco Advisers, Inc.
1.88M
3.39%
+1.12M
+147.36%
Mar 31, 2025
Ophir Asset Management Pty Ltd
1.62M
2.91%
+1.62M
--
Mar 31, 2025
Hood River Capital Management LLC
1.58M
2.84%
+1.58M
--
Mar 31, 2025
Fred Alger Management, LLC
1.43M
2.58%
-179.38K
-11.11%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ARK Genomic Revolution ETF
3.93%
Invesco Biotechnology & Genome ETF
2.95%
ROBO Global Healthcare Technology & Innovation ETF
1.43%
Invesco Dorsey Wright Healthcare Momentum ETF
1.43%
Global X Genomics & Biotechnology ETF
1.3%
Franklin Genomic Advancements ETF
0.52%
Main Thematic Innovation ETF
0.42%
SPDR S&P Biotech ETF
0.35%
First Trust Small Cap Growth AlphaDEX Fund
0.24%
VictoryShares US Small Mid Cap Value Momentum ETF
0.24%
Ver Mais
ARK Genomic Revolution ETF
Proporção3.93%
Invesco Biotechnology & Genome ETF
Proporção2.95%
ROBO Global Healthcare Technology & Innovation ETF
Proporção1.43%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção1.43%
Global X Genomics & Biotechnology ETF
Proporção1.3%
Franklin Genomic Advancements ETF
Proporção0.52%
Main Thematic Innovation ETF
Proporção0.42%
SPDR S&P Biotech ETF
Proporção0.35%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.24%
VictoryShares US Small Mid Cap Value Momentum ETF
Proporção0.24%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
